Eli Lilly And Co Drug Patent Portfolio

Eli Lilly And Co owns 10 orange book drugs protected by 31 US patents with Prozac having the least patent protection, holding only 1 patent. And Axiron with maximum patent protection, holding 11 patents. Given below is the list of Eli Lilly And Co's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
Active
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
Active
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
Active
US7855211 Protein kinase inhibitors 28 Sep, 2031
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
Active
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
Active
US8419307 Spreading implement 26 Feb, 2027
Active
US8807861 Spreading implement 26 Feb, 2027
Active
US9289586 Spreading implement 26 Feb, 2027
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026
Active
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026
Active
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024 Expired
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023 Expired
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023 Expired
US6034054 Stable insulin formulations 11 Jun, 2018 Expired
US6551992 Stable insulin formulations 11 Jun, 2018 Expired
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017 Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017 Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017 Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Eli Lilly And Co.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2024 US9474780
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2024 US9474780
Patent Issue Date Used in PTA Calculation 05 Mar, 2024 US11918623
Email Notification 05 Mar, 2024 US11918623
Patent eGrant Notification 05 Mar, 2024 US11918623
Patent eGrant Notification 05 Mar, 2024 US11918623
Mail Patent eGrant Notification 05 Mar, 2024 US11918623
Patent Issue Date Used in PTA Calculation 05 Mar, 2024 US11918623
Recordation of Patent Grant Mailed 05 Mar, 2024 US11918623
Email Notification 05 Mar, 2024 US11918623
Recordation of Patent eGrant 05 Mar, 2024 US11918623
Recordation of Patent eGrant 05 Mar, 2024 US11918623
Recordation of Patent Grant Mailed 05 Mar, 2024 US11918623
Mail Patent eGrant Notification 05 Mar, 2024 US11918623
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9474780


Eli Lilly And Co Drug Patents' Oppositions Filed in EPO

Eli Lilly And Co drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 26, 2017, by Müller Fottner Steinecke Rechtsanwalts- Und Patentanwaltspartnerschaft Mbb. This opposition was filed on patent number EP03729716A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11838771A Apr, 2020 Concert Pharmaceuticals, Inc. Granted and Under Opposition
EP06741180A Aug, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked
EP03729716A Apr, 2017 Müller Fottner Steinecke Rechtsanwalts- und Patentanwaltspartnerschaft mbB Revoked


Eli Lilly And Co's Family Patents

Eli Lilly And Co drugs have patent protection in a total of 54 countries. It's US patent count contributes only to 17.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Eli Lilly And Co Drug List

Given below is the complete list of Eli Lilly And Co's drugs and the patents protecting them.


1. Axiron

Axiron is protected by 11 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8435944 Method and composition for transdermal drug delivery 27 Sep, 2027
(2 years from now)
Active
US8419307 Spreading implement 26 Feb, 2027
(2 years from now)
Active
US8807861 Spreading implement 26 Feb, 2027
(2 years from now)
Active
US9289586 Spreading implement 26 Feb, 2027
(2 years from now)
Active
US8993520 Method and composition for transdermal drug delivery 02 Jun, 2026
(1 year, 7 months from now)
Active
US9180194 Method and composition for transdermal drug delivery 02 Jun, 2026
(1 year, 7 months from now)
Active
US8784878 Transdermal delivery rate control using amorphous pharmaceutical compositions 13 Jul, 2023
(1 year, 3 months ago)
Expired
US6299900 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(7 years ago)
Expired
US6818226 Dermal penetration enhancers and drug delivery systems involving same 19 Feb, 2017
(7 years ago)
Expired
US6923983 Transdermal delivery of hormones 19 Feb, 2017
(7 years ago)
Expired
US8071075 Dermal penetration enhancers and drug delivery systems involving the same 19 Feb, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axiron's drug page


2. Humalog Kwikpen

Humalog Kwikpen is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7291132 Medication dispensing apparatus with triple screw threads for mechanical advantage 09 Aug, 2024
(2 months ago)
Expired
US6034054 Stable insulin formulations 11 Jun, 2018
(6 years ago)
Expired
US6551992 Stable insulin formulations 11 Jun, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Humalog Kwikpen's drug page


3. Mounjaro

Mounjaro is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro's drug page


4. Mounjaro (autoinjector)

Mounjaro (autoinjector) is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(11 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(6 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mounjaro (autoinjector)'s drug page


5. Olumiant

Olumiant is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections 30 Nov, 2032
(8 years from now)
Active
US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections 30 Nov, 2032
(8 years from now)
Active
US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors 31 May, 2032
(7 years from now)
Active
US11806555 Methods for treating hair loss disorders 02 Nov, 2031
(7 years from now)
Active
US9737469 Methods for treating hair loss disorders 02 Nov, 2031
(7 years from now)
Active
US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors 10 Mar, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olumiant's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Prozac

Prozac is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6960577 Combination therapy for treatment of refractory depression 01 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prozac's drug page


7. Reyvow

Reyvow is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12071423 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate 06 Jul, 2040
(15 years from now)
Active
US11053214 Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists 05 Dec, 2037
(13 years from now)
Active
US7423050 Pyridinoylpiperidines as 5-HT1F agonists 17 Feb, 2028
(3 years from now)
Active
US8748459 Pyridinoylpiperidines as 5-HT1F agonists 27 Mar, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyvow's drug page


8. Verzenio

Verzenio is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7855211 Protein kinase inhibitors 28 Sep, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verzenio's drug page


9. Zepbound

Zepbound is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound's drug page


10. Zepbound (autoinjector)

Zepbound (autoinjector) is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357820 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US11918623 GIP/GLP1 agonist compositions 14 Jun, 2039
(14 years from now)
Active
US9474780 GIP and GLP-1 co-agonist compounds 05 Jan, 2036
(11 years from now)
Active
US9402957 Automatic injection device with delay mechanism including dual functioning biasing member 29 Jun, 2031
(6 years from now)
Active
US8734394 Automatic injection device with delay mechanism including dual functioning biasing member 24 Feb, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepbound (autoinjector)'s drug page


Eli Lilly And Co News

FDA reports that there is no longer a shortage of Eli Lilly's weight-loss medication - as per The Washington Post

03 Oct, 2024

Cork leads the way in the pharmaceutical industry's newest breakthrough medication - Report from the Irish Examiner

13 Sep, 2024

Potential of Eli Lilly's popular drug Tirzepatide in reducing risk for obesity and diabetes shown in a recent study - Benzinga

20 Aug, 2024

The CEO of Lilly anticipates the end of weight-loss drug shortage in the near future, as stated by ET HealthWorld.

02 Aug, 2024

See More